Acarbose Kept Old Mice Sharp, Blunting Blood Sugar Spikes Seems to Protect the Aging Brain
RapAdmin
Researchers at the University of Michigan tested whether acarbose, a generic diabetes drug that reliably extends mouse lifespan, also protects the aging brain. They fed acarbose at 1000 ppm to genetically diverse mice starting at four months of age, then measured spatial learning and memory in the Morris water maze at six, twelve, and twenty-four months. In normally aging mice, acarbose did nothing at six months, produced a modest benefit at twelve months, and meaningfully preserved spatial memory at twenty-four months, where treated animals searched for a hidden platform about as accurately as young adults. The drug was not a cognitive enhancer. It specifically offset age-related decline, and the benefit grew with age. In sibling mice carrying five familial Alzheimer’s mutations, acarbose produced no cognitive benefit at any age despite clear evidence the drug was working metabolically. The authors conclude that Alzheimer’s disease is not simply accelerated aging.
For twenty years the field has had a short list of drugs that make mice live longer. Acarbose sits near the top of that list. It is an old, cheap, FDA-approved diabetes pill that blocks the enzymes which break complex carbohydrates into glucose, so sugar enters the bloodstream slowly instead of in a spike after meals. The National Institute on Aging’s Interventions Testing Program showed that feeding it to genetically diverse mice from four months of age adds roughly a fifth to male median lifespan.
What nobody had properly tested is whether those extra months are worth having. Lifespan is easy to measure. Cognition is not, and the two can come apart. A drug that keeps a mouse alive while its mind goes is not a geroprotector anyone wants.
Shannon Moore and Geoffrey Murphy at the University of Michigan set out to answer that question with an unusually clean design. They took the four-way breeding cross the Interventions Testing Program uses to generate genetically unique mice, then swapped one grandparent strain for a mouse carrying five human mutations that cause early-onset Alzheimer’s. The result was litters of siblings raised in the same cages, where half carried the Alzheimer’s mutations and half did not. Same genetic background, same food, same room, same experimenter. The only difference was the disease.
Mice went on acarbose chow at four months, then separate groups were tested in the Morris water maze at six, twelve, or twenty-four months. The maze is a pool of opaque water with a hidden platform. Mice learn where the platform is from posters on the walls. Remove the platform and a mouse that remembers will swim in tight circles over the spot it used to be.
In the normally aging mice, the pattern was striking in its specificity. At six months, acarbose did exactly nothing to cognition. At twelve months, treated mice figured out the platform location faster than controls. At twenty-four months, the gap was clear: control mice needed the full twelve days of training before they searched the right area better than random chance, while acarbose-treated mice got there in six days and held that performance, looking essentially like young adults.
That age pattern matters more than the headline. A drug that improved young mice would be a stimulant. A drug that only helps old mice is doing something to aging itself.
Then the Alzheimer’s mice. Nothing. No improvement in learning, no improvement in memory, at any age, in either sex. The drug was clearly getting in and working, because it dropped body weight in those animals just as much as in their healthy siblings. The metabolic lever was being pulled. The brain did not respond.
The uncomfortable detail sits in the probe trials. In the middle-aged and aged Alzheimer’s cohorts, treated mice actually took longer than untreated ones to show they remembered the platform. The difference was not statistically significant, so it may be noise. But the authors raise the possibility they are obliged to raise: if acarbose keeps sick animals alive without protecting their minds, it extends the duration of impairment rather than shortening it.
Actionable Insights
Effect size, in plain terms, asks how far apart two groups are relative to how much individuals vary. A Cohen’s d of 0.2 is small, 0.5 moderate, 0.8 large. For the headline finding, memory in aged healthy mice, the gap works out to about d = 0.66. Moderate. Real, but not transformative, and roughly the size of effect that often shrinks on replication.
The more intuitive number is training time. Aged control mice needed four probe trials and twelve days of training before they searched the target area above chance. Aged acarbose mice needed two probes and six days. That is a halving of the learning time required, and it is the figure worth carrying.
Three practical points. First, timing. These mice were dosed from four months, roughly human young adulthood, for twenty months. This is a prevention result, not a rescue result, and nothing here says starting at seventy would work. Second, dose. The chow concentration translates to roughly 115 mg/kg/day in mice, which by body surface area scaling is near 650 mg/day for a 70 kg human, about twice the maximum approved dose. Third, and most important, the drug did nothing once Alzheimer’s pathology was present. Metabolic optimization is not an amyloid strategy.
Context and Source
- Open Access Paper: Acarbose ameliorates age-related spatial learning and memory deficits in a mouse model of normal aging but not Alzheimer’s disease.
- Institution: University of Michigan Medical School, Ann Arbor, Michigan, USA. Departments of Molecular and Integrative Physiology, Neurology, and the Michigan Neuroscience Institute.
- Country: United States.
Journal: GeroScience, official journal of the American Aging Association. - Impact evaluation: The impact score of this journal is 6.0 (2025 Journal Impact Factor, with a 5-year figure of 6.2), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.









